Is NCT07213791 recruiting in Boston, MA?

Yes, NCT07213791 is currently recruiting participants at its Boston, MA location. This ovarian neoplasms clinical trial is actively enrolling qualified participants.

How do I join the ovarian neoplasms clinical trial in Boston?

To join this clinical trial in Boston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Boston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Ovarian Neoplasms Clinical Trial in Boston, MA

About This Ovarian Neoplasms Study in Boston

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.

Sponsor: Eli Lilly and Company

Who Can Participate

Inclusion Criteria

Must have clinical or imaging evidence of fibroblast activation protein (FAP) expression per local assessment

Must have histologically or cytologically confirmed diagnosis of one of the following:

Adenocarcinoma of the pancreas

Hormone receptor (HR)-positive human epidermal growth factor 2 (HER2)-negative breast cancer

HER2-positive breast cancer

Triple negative breast cancer (TNBC)

Platinum-resistant or refractory ovarian cancer (including ovarian carcinosarcoma)

Other solid tumors

Gastric cancer (adenocarcinoma)

Colorectal cancer (CRC)

Esophageal cancer (squamous cell carcinoma or adenocarcinoma)

Cholangiocarcinoma

Must have received prior treatments as indicated below:

Adenocarcinoma of the pancreas: Participants must have received at least 1, but no more than 2 prior regimens for locally advanced unresectable or metastatic disease.

HR-positive HER2-negative breast cancer: Participants must have received less than or equal to (≤)5 prior lines of treatment for advanced or metastatic disease, which must include a cyclin-dependent kinase 4/6 inhibitor.

HER2-positive breast cancer: Participants must have received at least 2 lines of HER2-targeted therapy, which should include at least 1 antibody-drug conjugate (ADC) for metastatic disease (if locally available).

TNBC: Participants must have received at least 2 lines of therapy for metastatic disease.

Platinum-resistant or refractory ovarian cancer: Participants must have received or after at least 1 platinum-based therapy.

Other solid tumors (gastric cancer, CRC, esophageal and cholangiocarcinoma): Participants must have received greater than or equal to (≥)1 prior line of systemic therapy for advanced or metastatic disease; including prior line(s) in combination with immunotherapy or vascular endothelial growth factor inhibitor.

Participants must have advanced or metastatic solid tumors and have received ≥1 prior line of therapy.

Must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1.

Measured creatinine clearance ≥60 milliliters per minute (mL/min)

Exclusion Criteria

Have known active central nervous system (CNS) metastases or carcinomatous meningitis.

Have significant cardiovascular disease

Have prolongation of the corrected QTcF \>470 milliseconds (msec) during screening. QTcF is calculated using Fridericia's Formula: QTcF = QT/(RR0.33)

Have evidence of ongoing and untreated urinary tract obstruction

Had previous hemi- or total-body radiation.

Had previous adoptive T-cell therapy (e.g., chimeric antigen receptor T-cell \[CAR-T therapy, T-cell receptor \[TCR\] therapy, etc.)

Unable to lie flat during, or otherwise tolerate, single photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT) or magnetic resonance imaging (MRI).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT07213791) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ovarian Neoplasms Treatment Options in Boston, MA

If you're searching for ovarian neoplasms treatment options in Boston, MA, this clinical trial (NCT07213791) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ovarian neoplasms specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ovarian neoplasms clinical trials near you to find additional studies recruiting in your area.

Ovarian Neoplasms Clinical Trial in Boston, MA

Expert Care in Boston

IRB Approved

No-Cost Care

Apply for This Boston Location

Why Participate?

Simple Process